DUBLIN--(BUSINESS WIRE)--The "Peptide Therapeutics Market Research Report by Technology (Hybrid Phase, Liquid Phase, and Solid Phase), API Type, Drug Class, Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Peptide Therapeutics Market size was estimated at USD 24,461.45 million in 2020, USD 27,134.60 million in 2021, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.97% to reach USD 45,681.04 million by 2026.
In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Cumulative Impact of COVID-19:
The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.
It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.
Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
- AmbioPharm Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bachem Holding AG
- Bristol-Myers Squibb Company
- CordenPharma International
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Hemmo Pharmaceuticals Pvt Ltd.
- Ipsen S.A.
- Merck & Co., Inc.
- Novartis International AG
- Novo Nordisk A/S
- Pfizer Inc.
- PolyPeptide Group
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Zealand Pharma A/S
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer, cardiovascular disorders (CVDs) and metabolic disorder
5.1.1.2. Technology advancement and R & D investment in new peptides
5.1.2. Restraints
5.1.2.1. Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides
5.1.3. Opportunities
5.1.3.1. Presence of strong product pipeline portfolio
5.1.3.2. Adoption of new platforms that develop next-generation protein or peptide therapeutics
5.1.4. Challenges
5.1.4.1. Presence of stringent safety regulations
5.2. Cumulative Impact of COVID-19
6. Peptide Therapeutics Market, by Technology
6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase
7. Peptide Therapeutics Market, by API Type
7.1. Introduction
7.2. CMO
7.3. In-house
8. Peptide Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Calcitonins
8.3. Glucagon & Analogs
8.4. Insulins
8.5. Luteinizing Hormone-Releasing Hormone
8.6. Somatostatins
8.7. Vasopressin
9. Peptide Therapeutics Market, by Application
9.1. Introduction
9.2. Anti-infective
9.3. Cancer
9.4. Cardio Vascular Disease Respiratory
9.5. Central Nervous System
9.6. Dermatology
9.7. Gastrointestinal
9.8. Metabolic
9.9. Renal
10. Peptide Therapeutics Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Pharmaceutical Industries
10.4. Research Laboratories
11. Americas Peptide Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Peptide Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
13. Europe, Middle East & Africa Peptide Therapeutics Market
13.1. Introduction
13.2. France
13.3. Germany
13.4. Italy
13.5. Netherlands
13.6. Qatar
13.7. Russia
13.8. Saudi Arabia
13.9. South Africa
13.10. Spain
13.11. United Arab Emirates
13.12. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
For more information about this report visit https://www.researchandmarkets.com/r/xot8n5
